{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:57:01Z","timestamp":1793451421003,"version":"4.5.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the efficacy, effectiveness and safety of recombinant zoster vaccine (RZV) and zoster vaccine live (ZVL) in immunocompetent and immunocompromised subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data sources: PubMed, EMBASE, Cochrane Library, and Web of Science databases (up to Jan 2022) were searched to identify English articles. Search terms included randomized controlled trials (RCTs), observational studies, herpes zoster, RZV, ZVL. Study Selection: Only randomized controlled trials (RCTs) evaluating vaccine efficacy and safety and observational studies assessing vaccine effectiveness (after a vaccine was approved for marketing) were included. Data Extraction: Two researchers independently screened the literature, extracted the data, and checked the each other results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen RCTs and 19 cohort studies were included. Among immunocompetent subjects, RZV was superior to ZVL at wide intervals (relative vaccine efficacy: 84%, 95% CI: 53%\u201395%; relative vaccine effectiveness: 49%, 95% CI: 21%\u201367%), across genders and subjects aged \u2265 60 years. Among immunocompromised subjects, RZV was superior to placebo in terms of vaccine efficacy (60%, 95% CI: 49%\u201369%). There was no difference between ZVL and placebo in those with selected immunosuppressive conditions. RZV was 45% (95% CI: 30%\u201359%) superior to ZVL in real-world practice. Compared with placebo, adverse events related to RZV were primarily related to injection-site and systemic, and RZV did not increase the risk of serious adverse events (SAEs) or death. There was no difference in the incidence of adverse events between groups with and without immunosuppression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Both RZV and ZVL can reduce the risk of herpes zoster in both immunocompetent and immunocompromised subjects. RZV was well-tolerated in the study population and demonstrated stronger protection than ZVL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p>Prospero CRD42022310495.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.978203","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T08:28:27Z","timestamp":1664526507000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":68,"title":["Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yue","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuren","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanxi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201808070","article-title":"Herpes zoster","volume":"169","author":"Schmader","year":"2018","journal-title":"Ann Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a united states administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Intern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"van Oorschot","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"g2911","DOI":"10.1136\/bmj.g2911","article-title":"Quantification of risk factors for herpes zoster: population based case-control study","volume":"348","author":"Forbes","year":"2014","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.05.598","article-title":"Treatment of community-acquired pneumonia in immunocompromised adults: A consensus statement regarding initial strategies","volume":"158","author":"Ramirez","year":"2020","journal-title":"Chest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.12.013","article-title":"Incidence and disease burden of herpes zoster in the population aged >\/=50 years in China: Data from an integrated health care network","volume":"82","author":"Sun","year":"2021","journal-title":"J Infect"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.08.018","article-title":"Incidence of herpes zoster and its complications in Germany, 2005-2009","volume":"70","author":"Hillebrand","year":"2015","journal-title":"J Infect"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020528","article-title":"Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the clinical practice research datalink 2000-2012","volume":"8","author":"Yanni","year":"2018","journal-title":"BMJ Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.06.016","article-title":"A population based study of the epidemiology of herpes zoster and its complications","volume":"67","author":"Weitzman","year":"2013","journal-title":"J Infect"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.06.010","article-title":"Incidence of herpes zoster amongst adults varies by severity of immunosuppression","volume":"75","author":"Schroder","year":"2017","journal-title":"J Infect"},{"key":"B14","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"B15","first-page":"1528","article-title":"Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"k5095","DOI":"10.1136\/bmj.k5095","article-title":"Herpes zoster infection","volume":"364","author":"Le","year":"2019","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: A randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"Jama"},{"key":"B23","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged >\/=19 years: Recommendations of the advisory committee on immunization practices - united states, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.10.036","article-title":"Effectiveness of lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study","volume":"25","author":"Fu","year":"2007","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1983","article-title":"Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease","volume":"305","author":"Tseng","year":"2011","journal-title":"Jama"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001420","article-title":"Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study","volume":"10","author":"Langan","year":"2013","journal-title":"PloS Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab121","article-title":"Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the united states: A claims-based cohort study","volume":"73","author":"Sun","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant zoster vaccine (Shingrix): Real-world effectiveness in the first 2 years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? it all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-p) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0268-8","article-title":"Burden of herpes zoster in the Japanese population with Immunocompromised\/Chronic disease conditions: Results from a cohort study claims database from 2005-2014","volume":"9","author":"Imafuku","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1002\/sim.8158","article-title":"Network meta-analysis of rare events using the mantel-haenszel method","volume":"38","author":"Efthimiou","year":"2019","journal-title":"Stat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"key":"B36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"B37","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"Int J Epidemiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.11.17982","article-title":"Safety and tolerability of zoster vaccine in adults \u226560 years old","volume":"7","author":"Murray","year":"2011","journal-title":"Hum Vaccin"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.11.096","article-title":"Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults \u226560 years of age","volume":"30","author":"Vermeulen","year":"2012","journal-title":"Vaccine"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.090","article-title":"Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic\/maintenance corticosteroids","volume":"33","author":"Russell","year":"2015","journal-title":"Vaccine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy242","article-title":"Safety and immunogenicity of zoster vaccine live in human immunodeficiency virus-infected adults with CD4+ cell counts >200 Cells\/mL virologically suppressed on antiretroviral therapy","volume":"67","author":"Benson","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e12874","DOI":"10.1111\/tid.12874","article-title":"A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation","volume":"20","author":"Miller","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215925","article-title":"Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial","volume":"78","author":"Mok","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial","volume":"125","author":"Vink","year":"2019","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: A phase 3, randomized clinical trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.08.037","article-title":"Assessing the effectiveness of zoster vaccine live: A retrospective cohort study using primary care data in the united kingdom","volume":"36","author":"Matthews","year":"2018","journal-title":"Vaccine"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"Jama"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw854","article-title":"Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older","volume":"64","author":"Izurieta","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.021","article-title":"Effectiveness of herpes zoster vaccination in an older united kingdom population","volume":"36","author":"Walker","year":"2018","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ930","article-title":"Effectiveness of herpes zoster vaccine in patients 60 years and older with end-stage renal disease","volume":"62","author":"Tseng","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.06.008","article-title":"Effectiveness of the herpes zoster vaccine zostavax\u00ae in Stockholm county, Sweden","volume":"37","author":"Blom","year":"2019","journal-title":"Vaccine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.01.067","article-title":"Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia","volume":"39","author":"Lin","year":"2021","journal-title":"Vaccine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160685","article-title":"Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases","volume":"44","author":"Yun","year":"2017","journal-title":"J Rheumatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.017","article-title":"Effectiveness of the recombinant zoster vaccine for herpes zoster ophthalmicus in the united states","volume":"128","author":"Lu","year":"2021","journal-title":"Ophthalmology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.056","article-title":"Effectiveness of the recombinant zoster vaccine among kaiser permanente Hawaii enrollees aged 50 and older: A retrospective cohort study","volume":"39","author":"Sun","year":"2021","journal-title":"Vaccine"},{"key":"B61","doi-asserted-by":"publisher","first-page":"R174","DOI":"10.1186\/ar3497","article-title":"The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study","volume":"13","author":"Zhang","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu498","article-title":"Vaccination against zoster remains effective in older adults who later undergo chemotherapy","volume":"59","author":"Tseng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.07.004","article-title":"Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention","volume":"37","author":"Klein","year":"2019","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.jvacx.2019.100007","article-title":"Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England","volume":"1","author":"Bollaerts","year":"2019","journal-title":"Vaccine X"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.DMIH2-0026-2016","article-title":"Overview of infections in the immunocompromised host","volume":"4","author":"Dropulic","year":"2016","journal-title":"Microbiol Spectr"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of shingrix, a recombinant glycoprotein e adjuvanted herpes zoster vaccine","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2005.12.002","article-title":"Gender as an independent risk factor for herpes zoster: a population-based prospective study","volume":"16","author":"Opstelten","year":"2006","journal-title":"Ann Epidemiol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121484","article-title":"Th1 memory differentiates recombinant from live herpes zoster vaccines","volume":"128","author":"Levin","year":"2018","journal-title":"J Clin Invest"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab580","article-title":"Cell-mediated immune responses after administration of the live or the recombinant zoster vaccine: 5-year persistence","volume":"225","author":"Johnson","year":"2022","journal-title":"J Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.978203\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T08:28:31Z","timestamp":1664526511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.978203\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":69,"alternative-id":["10.3389\/fimmu.2022.978203"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.978203","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"article-number":"978203"}}